<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Registrations</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:30-09:50</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>09:50-11:50</td>
<td>MEETING HALL 01</td>
</tr>
<tr>
<td>11:50-13:10</td>
<td>Talks On:</td>
</tr>
<tr>
<td></td>
<td>Human Vaccines - Infectious &amp; Non Infectious Diseases</td>
</tr>
<tr>
<td></td>
<td>Vaccine Research &amp; Development</td>
</tr>
<tr>
<td></td>
<td>Next-Generation Vaccine Technologies</td>
</tr>
<tr>
<td></td>
<td>Vaccine Safety &amp; Efficacy</td>
</tr>
<tr>
<td></td>
<td>Vaccine Delivery Innovations</td>
</tr>
<tr>
<td></td>
<td>Vaccines Business and Development</td>
</tr>
<tr>
<td></td>
<td>Vaccine Adjuvants</td>
</tr>
<tr>
<td>13:10-13:15</td>
<td>GROUP PHOTO</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td>14:00-16:00</td>
<td>MEETING HALL 01</td>
</tr>
<tr>
<td></td>
<td>Talks On:</td>
</tr>
<tr>
<td></td>
<td>HIV/AIDS Vaccines</td>
</tr>
<tr>
<td></td>
<td>Immunology / Animal Models</td>
</tr>
<tr>
<td></td>
<td>Childhood and Maternal Vaccines</td>
</tr>
<tr>
<td></td>
<td>Human Preventive &amp; Therapeutic Vaccines</td>
</tr>
<tr>
<td></td>
<td>Cancer Vaccines and Immunotherapy</td>
</tr>
<tr>
<td>16:00-16:20</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>16:20-17:00</td>
<td>MEETING HALL 01 (16:20-17:00)</td>
</tr>
<tr>
<td></td>
<td>Young Researchers in Immunization and Vaccinology</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM

Tuesday 04th June

09:00-10:30 Meeting Hall 01
KEYNOTE LECTURES

10:30-10:50 COFFEE BREAK

10:50-12:50 MEETING HALL 01
Talks On:
- Vaccines against Vector-borne Diseases
- Vaccines for Older Adults
- Veterinary vaccines
- Vaccines against Viral & Bacterial Diseases
- Vaccines for Respiratory Infections
- Plant-based Vaccines

12:50-13:35 LUNCH BREAK

13:35-15:55 MEETING HALL 01
Talks On:
- DNA Vaccines
- Hepatitis Vaccines
- Tuberculosis Vaccines
- Travel Immunization
- Mucosal vaccines
- HPV Vaccines

15:55-16:15 COFFEE BREAK

MEETING HALL 01 (16:15-17:00)
Poster Presentations

Awards & Closing Ceremony

Visit: https://europe.vaccineconferences.com/
Previous Organizing Committee Members

Frédéric J Deschamps
Reims University of Lille, France

Dennis Christensen
Statens Serum Institut, Denmark

Marek Malecki
Phoenix Biomolecular Engineering Foundation, USA

Giulio Filippo Tarro
Foundation T. & L. de Beaumont Bonelli for cancer research, Italy

Pierre A. Morgon
MRGN Advisors, Switzerland

Cyril Gerard Gay
United States Department of Agriculture, USA

Visit: https://europe.vaccineconferences.com/
Adrian Wildfire
SGS-Life Sciences, Belgium

Alexey Novokiv
LPS-Biosciences, France

Amirhossein Lotfi
Tehran University of Medical Sciences, Iran

Ana Gervassi
Center for Infectious Disease Research, USA

Andrew Cho
Konkuk University, South Korea

Baik Lin Seong
Yonsei University, South Korea

Brian Abel
A*STAR, Singapore

Carmen Alvarez-Dominguez
Instituto de Investigación Marqués de Valdecilla, Spain

Catherine Heffernan
NHS England, UK

Chang-Seon Song
Konkuk University, South Korea

Chanwoo Park
Konkuk University, South Korea

Chih-Hsiang Leng
National Health Research Institutes, Taiwan

Ching-Len Liao
National Health Research Institutes, Taiwan

Chit Laa Poh
Sunway University, Malaysia

Chutitorn Ketloy
Chulalongkorn University, Thailand

Clara Labaste
National Graduate School of Chemistry of Montpellier, France

Cyrielle Fougeroux
Copenhagen University, Denmark

Didier Clenet
Sanofi-Pasteur, France

Frederic J Deschamps
University Hospital of Reims, France

Fumihiko Takeshita
Daiichi Sankyo Co. Ltd., Japan

Gabriel Kristian Pedersen
Statens Serum Institut, Denmark

Geneviève Inchauspé
Transgene SA, France

Ger T Rijkers
University College Roosevelt, Netherlands

Godwin W Nchinda
Centre International de Reference Chantal Biya, Cameroon

Visit: https://europe.vaccineconferences.com/
Gyung Tae Chung  
*National Institute of Health, South Korea*

Helen Bright  
*Medimmune, UK*

Hengliang Wang  
*Beijing Institute of Biotechnology, China*

Hsin-Wei Chen  
*National Health Research Institutes, Taiwan*

Huyên T Pham  
*Konkuk University, South Korea*

Hyeran Won  
*National Institute of Health, South Korea*

Igor S Lukashevich  
*University of Louisville, USA*

Jean-François Bruxelle  
*University of Paris-Su, France*

Jean-François Fonteneau  
*INSERM, France*

Jei-Hyun Jeong  
*Konkuk University, South Korea*

Jin-yong Noh  
*Konkuk University, South Korea*

JiYoung Hong  
*National Institute of Food and Drug Safety Evaluation, South Korea*

Jun-beom Kim  
*Konkuk University, South Korea*

Jun-Young Kim  
*Konkuk University, South Korea*

Karola Rittner  
*Transgene SA, France*

Katherine Riccione  
*Duke University, USA*

Kathleen Hefferson  
*Cornell University, USA*

Kei Amemiya  
*US Army Medical Research Institute of Infectious Diseases, USA*

Kelly Haccuria  
*Johnson & Johnson, Belgium*

Keshe Bithia  
*National Bilingual Vocational Training Centre, Cameroon*

Kim Doh Hoon  
*Konkuk University, South Korea*

Klaus Schwamborn  
*Valneva SE, France*

Kongmany Chaluenvong  
*University of Health Sciences, Laos*

Lina Perron  
*CISSS Montérégie-Center, Canada*
Lucy Rumbellow  
*NHS England, UK*

Magdalena Tary-Lehmann  
*Cellular Technology Limited, USA*

Mark Fife  
*The Pirbright Institute, UK*

Ming-Hsi Huang  
*National Health Research Institutes, Taiwan*

Mohammad Hossein Yazdi  
*Tehran University of Medical Sciences, Iran*

Nelly Papin  
*Gyros Protein Technologies, France*

Park Dam-hee  
*Konkuk University, South Korea*

Pascal Breton  
*VitamFero, France*

Peter Johannes Holst  
*University of Copenhagen, Denmark*

Pragya Sharma  
*Maulana Azad Medical College, India*

Randa S Hamadeh  
*Ministry of Public Health, Lebanon*

Sadao Suzuki  
*Nagoya City University, Japan*

Shan Lu  
*University of Massachusetts Medical School, USA*

Sun Shin Yi  
*Soonchunhyang University, Republic of Korea*

Sung Kwan Hong  
*CHA University, South Korea*

Touraj Aligholipour Farzani  
*Ankara University, Turkey*

Vanphanom Sychareun  
*University of Health Sciences, Laos*

Visanou Hansana  
*University of Health Sciences, Laos*

Vu Thi Thu Nga  
*Du an Dai hoc VinUni, Vietnam*

Wei-Cai Zhang  
*Beijing Institute of Biotechnology, China*

Weiping Zhang  
*Kansas State University, USA*

Xiao-Song He  
*VA Palo Alto Health Care System, USA*

Zrinka Oreskovic  
*Veterinary Research Institute, Czech Republic*
Glimpses of Vaccines Conferences

Visit: https://europe.vaccineconferences.com/
Scientific Program

31st Euro Global Summit and Expo on Vaccines & Vaccination & 4th World Congress and Exhibition on Antibiotics and Antibiotic Resistance

June 14-16, 2018 | Barcelona, Spain

UK: Conference Series llc LTD
47 Churchfield Road, London, W3 6AY
Toll Free: +0-800-014-8923
### Keynote Forum

**Title:** Targeted delivery in rational vaccine design  
*Gabriel Kristian Pedersen,* Statens Serum Institut, Denmark  
**Title:** Listeria based nanovaccines as therapeutic vaccines  
*Carmen Alvarez-Dominguez,* Instituto de Investigación Marqués de Valdecilla, Spain

### Session -1

**Title:** Overcoming antibiotic resistance: Inhibition of ld-transpeptidation in multi-drug resistant pathogens  
*Mario A Bianchet,* Johns Hopkins School of Medicine, USA  
**Title:** Kinugasa reaction as an attractive method of the synthesis of β-lactam drugs  
*Marek Chmielewski,* Polish Academy of Sciences, Poland

### Session Introduction

**Title:** Polio: An international threat  
*Randa S Hamadeh,* Ministry of Public Health, Lebanon  
**Title:** Perspectives of vaccinators on the factors affecting uptake of MenACWY vaccine amongst school leavers in London  
*Catherine Heffernan,* Public Health England, UK

### Lunch Break

**Title:** Nanovaccines to prevent neonatal listeriosis  
*Carmen Alvarez-Dominguez,* Instituto de Investigación Marqués de Valdecilla, Spain  
**Title:** Implications of IPV introduction in national immunization schedule and strategies to combat shortages  
*Pragya Sharma,* Maulana Azad Medical College, India  
**Title:** Investigations into the reduced effectiveness of the H1N1pdm09 component of the live attenuated influenza vaccine  
*Helen Bright,* Medimmune, UK

### Session -2

**Title:** Antibacterial and anti-biofilm activity of novel compounds of arctic marine origin  
*Klara Stensvag,* University of Tromsø - The Arctic University of Norway, Norway  
**Title:** Functional genomics and transcriptomics of virulent and multidrug resistant *Escherichia coli* of poultry origin  
*Haihong Hao,* Huazhong Agricultural University, China
<table>
<thead>
<tr>
<th>Networking &amp; Refreshment Break</th>
</tr>
</thead>
</table>
| **Title:** Cytotoxic and antiradical activity of roseofungin  
Iskakova Zhanar Baktybaevna, Kazakh University of Technology and Business, Kazakhstan |
| **Title:** Binding modes of teixobactin to Lipid II: Molecular dynamics study  
Yuguang Mu, Nanyang Technological University, Singapore |
| **Title:** Imipenem and meropenem Drug Utilization Evaluation (DUE) in the Social Security Hospital in Khorraramabad  
Amin Noori, Social Security Hospital, Iran |
| Panel Discussion |
| Day 2 June 15, 2018  
Hall - Linate |
| **Keynote Forum** |
| **Title:** HIV universal vaccine  
Marek Malecki, Phoenix Biomolecular Engineering Foundation, USA |
| **Title:** Vaccinations in working populations  
Frederic J Deschamps, University Hospital of Reims, France |
| Networking & Refreshment Break |
| **Title:** Metal nanoparticles as a novel tool to fight microbial biofilm development and antibiotic-resistance emergency  
Roberto Grau, Universidad Nacional de Rosario, Argentina |
| **Title:** Aminoglycoside antibiotics and hearing loss  
María Rosa Cháig, Bioquímica y Biología Molecular, Argentina |
| Sessions: HIV Vaccines | Vaccine Research & Development | Human Vaccines - Infectious & Non Infectious Diseases | Veterinary Vaccines | Vaccines against Viral & Bacterial Diseases |
| Session Chair: Chit Laa Poh, Sunway University, Malaysia |
| **Session Introduction** |
| **Title:** Targeting conserved broadly neutralizing epitopes within HIV-1 envelope gp41 MPER as vaccine immunogens for seronegative partners of HIV-1 discordant couples  
Godwin W Nchinda, CIRCB, Cameroon |
| **Title:** Repeated influenza vaccination is a potential cause for reduced B cell response in the elderly  
Xiao-Song He, VA Palo Alto Health Care System, USA |
| Lunch Break |
| **Title:** Chicken IFITM gene knockout technology for enhanced vaccine production  
Mark Fife, The Pirbright Institute, UK |
| **Title:** MicroRNA reduction of enterovirus 71 viral replication attenuates and confers protective immune response in mice  
Chit Laa Poh, Sunway University, Malaysia |
| **Poster Presentation** |
| **Antibiotics and Antibiotic Resistance** |
| **ANTB001**  
Title: Pharmacokinetics/pharmacodynamics modeling of cyadox against *Clostridium perfringens* in pigs  
Lingli Huang, Huazhong Agricultural University, China |
| **ANTB002**  
Title: New potent anti-Gram negative compounds from the myxobacteria *Coralloclados coralloides*  
Won Gon Kim, Korea Research Institute of Bioscience and Biotechnology, South Korea |
| **ANTB003**  
Title: Enterocin AP-CECT7121: Activity against human methicillin-resistant *Staphylococcus aureus* producers of biofilm  
Mónica Sparo, Universidad Nacional del Centro de la Provincia de Buenos Aires, Argentina |
| **ANTB004**  
Title: Detection of extended spectrum beta-lactamase producing *E. coli* isolated from different clinical specimens, Zahedan, Iran  
Shahnaz Armin, Shahid Beheshti University of Medical Sciences, Iran |
ANTB005  Title: Molecular detection antibiotic resistance in multidrug Acinetobacter baumannii isolated from west province of Iran
Leila Azimi, Shahid Beheshti University of Medical Sciences, Iran

ANTB006  Title: The peculiarities of tetraphenylphosphonium and ethidium interaction with Listeria monocytogenes and efficiencies of efflux
Sandra Sakalauskaite, Vytautas Magnus University, Lithuania

ANTB007  Title: The inhibitory effect of new phenothiazine derivatives of ABC transporters in Candida albicans
Neringa Kuliešiene, Vytautas Magnus University, Lithuania

Networking & Refreshment Break

Poster Presentation

Vaccines & Vaccination

EVACC 01  Title: Factors affecting uptake of MenACWY vaccination programme in schools: Insights from a London wide study
Lucy Rumbellow, Public Health England, UK

EVACC 02  Title: Implementing the evidence: Are call/recall systems for immunizations feasible?
Catherine Heffernan, Public Health England, UK

EVACC 03  Title: No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study
Sadao Suzuki, Nagoya City University, Japan

EVACC 04  Title: C-di-GMP as an effective microneedle vaccine adjuvant candidate on mouse
Andrew Cho, Konkuk University, South Korea

EVACC 05  Title: Lactic acid bacteria (Lab) as a potent adjuvant increase immunogenicity of reverse genetics derived H5N9 vaccines in domestic ducks
Jun-beom Kim, Konkuk University, South Korea

EVACC 06  Title: Efficacy and safety of inactivated Newcastle disease virus vaccines emulsified with two different oil adjuvants
Jei Hyun Jeong, Konkuk University, South Korea

EVACC 07  Title: Minimum infectious dose determination of the Korean isolated strain of infectious laryngotracheitis virus vaccine candidate strain by eye drop administration
Dam-Hee Park, Konkuk University, South Korea

EVACC 08  Title: Evaluation of the efficacy and oviduct lesion of novel recombinant live attenuated avian infectious bronchitis virus
Jun-Young Kim, Konkuk University, South Korea

EVACC 09  Title: Development of a novel thermostable Newcastle disease virus vaccine vector from wild bird origin
Jin-yong Noh, Konkuk University, South Korea

EVACC 10  Title: Study on vaccines of botulinum neurotoxin serotype A
Wei-Cai Zhang, Beijing Institute of Biotechnology, China

EVACC 11  Title: Design and production of conjugate vaccines against S. Paratyphi A using an o-linked glycosylation system in vivo
Hengliang Wang, Beijing Institute of Biotechnology, China

EVACC 12  Title: Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea
Hyeran Won, National Institute of Health, South Korea

Panel Discussion

Awards for Poster Presentations

Day 3 June 16, 2018

Extended Networking & Lunch
Scientific Program

16th Euro Global Summit and Expo on

VACCINES & VACCINATION

June 19-21, 2017  Paris, France
# Keynote Forum

**Introduction**

**Title:** DNA immunization to prime the high quality antigen-specific B cell responses – a powerful pathway to induce protective antibodies  
*Shan Lu*, University of Massachusetts Medical School, USA  
**Title:** Pan-Lassa fever vaccine for prevention and post-challenge applications  
*Igor S Lukashevich*, University of Louisville, USA

## Group Photo

**Title:** Altered vaccine immune responses to different Toll-Like receptor activators  
*Kei Amemiya*, US Army Medical Research Institute of Infectious Diseases, USA

## Networking & Refreshments Break

**Title:** Addressing challenges and solution for using T cell based assays for immune monitoring  
*Magdalena Tary-Lehmann*, Cellular Technology Limited, USA  
**Title:** Plant virus nanoparticles: New applications for developing countries  
*Kathleen Hefferon*, Cornell University, USA  
**Title:** Stability modeling to predict vaccine shelf-life and evaluate impact of temperature excursions from the “cold chain”  
*Didier Clenet*, Sanofi-Pasteur, France

## Lunch Break

**Title:** Multi-epitope fusion antigen (MEFA), novel technology for structural vaccinology  
*Weiping Zhang*, Kansas State University, USA  
**Title:** Singapore Immunology Network’s clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials  
*Brian Abel*, A*STAR, Singapore  
**Title:** Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication: Underappreciated role of location and immunodominance in vaccination against chronic infection  
*Peter Johannes Holst*, University of Copenhagen, Denmark

## Session Introduction

**Sessions:** Vaccine Research & Development | Cancer Vaccines | HIV Vaccines | Vaccine Adjuvants & Delivery Technologies  
**Session Chair:** Peter Johannes Holst, University of Copenhagen, Denmark

**Title:** Vaccination coverage cluster surveys in Middle Dreib–Akkar, Lebanon: Comparison of vaccination coverage in children aged 12-59 months pre- and post-vaccination campaign  
*Randa Hamadeh*, Ministry of Public Health, Lebanon  
**Title:** Responding to the threat of emergent infectious diseases  
*Klaus Schwamborn*, Valneva SE, France

## Network & Refreshments Break

**Title:** Polio outbreak stopped in the Middle East, efforts are still needed  
*Randa Hamadeh*, Ministry of Public Health, Lebanon

## Young Researchers Forum

**Title:** Modified MHCII associated invariant chain induces increased antibody responses against *Plasmodium falciparum* antigens after adenoviral vaccination  
*Cyrielle Fougeroux*, Copenhagen University, Denmark  
**Title:** Oil-based adjuvants and intradermal vaccine delivery: Th1 vs. Th2 response  
*Zrinka Oreskovic*, Veterinary Research Institute, Czech Republic
**Title:** Bovine herpesvirus type 4-BAC as an attractive viral vector for vaccination and gene therapy  
Touraj Aligholipour Farzani, Ankara University, Turkey

---

### Panel Discussion

---

### Day 2 | June 20, 2017 | Tuesday

**Sunset 2**

### Keynote Forum

**Title:** Live, attenuated vaccines in animal health: VitamFero’s products and a few others  
Pascal Breton, VitamFero, France

**Title:** Pneumococcal polysaccharide vaccines for elderly: Here, there and everywhere  
Ger T Rijkers, University College Roosevelt, Netherlands

---

**Sessions:** Immunization for Older Adults | Cancer Vaccines | Vaccines against Vector-borne Diseases | Human Preventive & Therapeutic Vaccines

**Session Chair:** Ger T Rijkers, University College Roosevelt, Netherlands

---

**Title:** Exploiting defects of type I interferon response in tumor cells for oncolytic immunotherapy with attenuated measles virus  
Jean-François Fonteneau, University of Nantes, France

**Title:** Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors  
Karola Rittner, Transgene SA, France

**Title:** Biogenic selenium nanoparticles can shift the immune response of breast cancer bearing mice toward Th1 pattern  
Mohammad Hossein Yazdi, Tehran University of Medical Sciences, Iran

**Title:** Recombinant lapidated subunit vaccines induce robust immunity against all four serotypes of dengue virus  
Hsin-Wei Chen, National Health Research Institutes, Taiwan

---

**Network & Refreshment Break**

---

**Title:** Therapeutic vaccination in chronic infectious diseases: The place of vectored vaccines  
Geneviève Inchauspé, Transgene SA, France

**Sessions:** Veterinary vaccines | Vaccine Research & Development | Vaccine Adjuvants & Delivery Technologies | HIV Vaccines

**Session Chair:** Pascal Breton, VitamFero, France

---

**Title:** A toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population  
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

**Title:** Development of innovative vaccines by the combination of novel technologies  
Fumihiko Takeshita, Daiichi Sankyo Co. Ltd., Japan

**Title:** Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and ameliorates vaccine efficacy  
Ming-Hsi Huang, National Health Research Institutes, Taiwan

**Title:** Kinetics of myeloid derived suppressor cells (MDSC) and their effect on vaccine-specific responses during the first year of life  
Ana Gervassi, Center for Infectious Disease Research, USA

---

**Network & Refreshment Break**

---

**Panel Discussion**

---

**Poster Presentations**

**EVACC 01**

**Title:** Development of a peptide vaccine platform for brain tumor immunotherapy that incorporates adjuvant CD27 stimulation for enhanced T cell immunity  
Katherine Riccione, Duke University, USA

**EVACC 02**

**Title:** *Clostridium difficile* flagellin FlIC as an adjuvant to induce a protective gut mucosal immune response  
Jean-François Bruxelle, University of Paris-Su, France
EVACC 03
Title: LPS/Endotoxins molecular diversity impacting vaccines and adjuvants activities and toxicity
Alexey Novokiv, LPS-Biosciences, France

EVACC 04
Title: Construction for minimal positive conditions for the safety of brain from vaccines to be supplied quickly at widespread epidemics
Sun Shin Yi, Soonchunhyang University, Republic of Korea

EVACC 05
Title: Development and preclinical evaluation of 15 pneumococcal polysaccharide CRM197 conjugate candidate vaccines in mouse model
Huyen T Pham, Konkuk University, South Korea

EVACC 06
Title: Study for establishment of 1st National Reference Standard for cell-derived Japanese encephalitis vaccine (Beijing strain)
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, South Korea

EVACC 07
Title: Flavivirus nonstructural protein 1-based recombinant vaccines
Ching-Len Liao, National Health Research Institutes, Taiwan

EVACC 08
Title: Heterologous prime-boost tetravalent dengue vaccine strategy elicits complete protection against DENV-2 in non-human primates
Chutitorn Ketloy, Chulalongkorn University, Thailand

Awards for Poster Presentations
Day 3 | June 21, 2017 | Wednesday
Extended Networking & Lunch

Bookmark your dates
30th Euro Global Summit and Expo on

Vaccines & Vaccination
Jun 21-23, 2018 Barcelona, Spain

E: eurovaccines@conferenceseries.net; eurovaccines@vaccineconference.com
W: vaccines.global-summit.com/europe
10th Euro Global Summit and Expo on Vaccines & Vaccination
June 16-18, 2016 Rome, Italy

Scientific Program

Hosting Organization: UK: Conference Series llc LTD
e-mail: eurovaccines@insightconferences.com; eurovaccines@conferenceseries.net
Day 1                June 16, 2016

Registrations

Opening Ceremony

Keynote Forum

Introduction

Title: Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention
Timothy R Fouts, Profectus Biosciences Inc., USA

Title: Vaccines moving beyond the next frontier
Rene Labatut, Sanofi Pasteur, USA

Networking & Refreshments Break

Session Introduction

Title: Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites
Ma Luo, University of Manitoba, Canada

Title: Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV
Qingsheng Li, University of Nebraska-Lincoln, USA

Title: TAT, the forgotten target that could help to cure from HIV
Erwann P Loret, ETRAV Laboratory, France

Title: Community engagement during the Ebola vaccine trial in Guinea
Godwin Enwere, World Health Organization, Switzerland

Title: Pre-clinical toxicology considerations in vaccine
Nabil Al-Humadi, Food and Drug Administration, USA

Lunch Break

Title: Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation
Bettina Werle, Bioaster, France

Title: Development of lipid based oral vaccine formulations
Sarah Margaret Hook, University of Otago, New Zealand

Title: Viral vectored genetic vaccines: Current status and future perspectives
Antonella Folgori, Reithera SRL, Italy

Title: Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia
Gunther Staffler, AFFiRiS AG, Austria

Title: Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study
Anissa Boumilic-Courtaude, Merck Life Science, France

Title: MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine
Duccio Medini, GSK Vaccines, Italy

Networking & Refreshments Break

Title: Implementing a randomized control trial (RCT) in the context of an Ebola epidemic
Godwin Enwere, World Health Organization, Switzerland

Title: Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
Peter Burkhard, Alpha-O Peptides AG, Switzerland

Title: Plant expression platforms for vaccine production
Kathleen Hefferon, Cornell University, USA
Title: What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities
Jacques Choucair, Saint Joseph University, Lebanon

Young Researchers Forum

Title: Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco
Ennima Imane, University Mohammed V of Rabat, Morocco

Title: Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco

Title: Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens
Khadija Khataby, University Hassan II of Casablanca, Morocco

Panel Discussion

Day 2 June 17, 2016

Appia

Keynote Forum

Title: Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein
Andrew Lees, Fina Biosolutions LLC, USA

Title: Human vaccines and vaccination for non-infectious diseases
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Networking & Refreshments Break

Title: Challenges and dilemmas about vaccines against the herpesviruses: The case of EBV
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases
Track 8: Viral Vaccines
Track 9: Bacterial Vaccines
Track 10: Childhood Vaccines
Track 11: Hepatitis Vaccines
Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
Andrew Lees, Fina Biosolutions LLC, USA

Session Introduction

Title: Rapid development of an oral Zika virus vaccine
Sean N Tucker, Vaxart Inc., USA

Title: Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections
Timothy R Fouts, Profectus Bio-Sciences, USA

Title: Measles: Need for continued vaccination and novel vaccines post virus eradication
S Louise Cosby, Agri-Food and Biosciences Institute, UK

Title: Evaluation of genetic stability of transgenes in vaccine
Ali Azizi, Sanofi Pasteur, Canada

Title: Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break

Title: Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA

Title: Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders
Jacques Choucair, Saint Joseph University, Lebanon

Panel Discussion
### Workshop on Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines

**Session Chairs:** Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy  
Felipe García Alcaide, Hospital Clinic de Barcelona, Spain

**Title:** Expanding the findings of RV144 to South Africa: P5 Initiative  
*Glenda Gray,* South African Medical Research Council, South Africa

**Title:** Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa  
*Barbara Ensoli,* National AIDS Center-Istituto Superiore di Sanità, Italy

<table>
<thead>
<tr>
<th>Networking &amp; Refreshments Break</th>
</tr>
</thead>
</table>

**Title:** Current strategies for HIV remission: The role of therapeutic vaccines  
*Felipe García Alcaide,* Hospital Clinic de Barcelona, Spain

**Title:** Synthetic DNA vaccines for difficult mucosal viruses including HIV  
*Jean D. Boyer,* Inovio Pharmaceuticals Inc., USA

**Title:** Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine  
*Adan Rios,* Photimmune Biotechnology Inc., USA

### Session Chairs: Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France  
Eric Sandstrom, Karolinska Institutet, Sweden

**Title:** HIV vaccine development: Is a moral wrong occurring?  
*Mike King,* University of Otago, New Zealand

**Title:** Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus  
*Marc H.V. Van Regenmortel,* Biotechnology School of the University of Strasbourg, France

**Title:** HIV replication is suppressed by CD8-T regulatory cells in elite controllers  
*Jean Marie Andrieu,* Paris-Descartes University, France

**Title:** Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+ cell HIV suppressive activity  
*Eric Sandstrom,* Karolinska Institutet, Sweden

### Poster Presentations

| EVACC 01 | Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response  
*Jae-Hwan Nam,* Catholic University of Korea, South Korea |
| EVACC 02 | Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging  
*Hyewon Youn,* Catholic University of Korea, South Korea |
| EVACC 03 | Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system  
*Sun Shin Yi,* Soonchunhyang University, South Korea |
| EVACC 04 | Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against *Fasciola gigantica* in mice  
*Narin Changkungnoo,* Burapha University, Thailand |
| EVACC 05 | Vaccine potentials of recombinant mature cathepsin L1H against *Fasciola gigantica* in mice  
*Pornanan Kueakhai,* Burapha University, Thailand |
| EVACC 06 | Characterization and vaccination of the cytosolic *Fasciola gigantica* superoxide dismutase  
*Wipaphorn Jaikua,* Mahidol University, Thailand |
| EVACC 07 | Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)  
*Ji Young Hong,* National Institute of Food and Drug Safety Evaluation, Korea |
| EVACC 08 | Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability  
*Suna Gu,* Chonbuk National University, Republic of Korea |
| EVACC 09 | In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species  
*Marwa Mohamed Osman,* Africa City of Technology, Sudan |

---

**Day 3  June 18, 2016**

**Appia**

Track 13: DNA Vaccines  
Track 14: Vaccine Safety and Efficacy  
Track 15: Vaccine Adjuvants  
Track 16: Tuberculosis Vaccines  
Track 17: Vaccination for Pregnant Women  
Track 18: Human Preventive and Therapeutic Vaccines
Title: Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring  
Sonali Kochhar, Global Healthcare Consulting, India

Title: Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials  
Timothy R Fouts, Profectus Biosciences Inc., USA

Title: Operational experience and lessons learned on influenza vaccination post authorization safety studies  
Ombretta Palucci, Quintiles, Switzerland

Title: Post-marketing surveillance of BCG vaccination  
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan

Title: Novel vaccine adjuvants for animal infectious diseases  
Jishu Shi, Kansas State University, USA

Title: Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation  
Ramesh Chintala, Merck & Co. Inc., USA

Title: Immunogenicity of VLP forming baculoviral DNA vaccine  
Young Bong Kim, Konkuk University, Republic of Korea

Title: Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species  
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan

Title: Therapeutic vaccines for treatment of allergic and autoimmune diseases  
Zhikang Peng, University of Manitoba, Canada

Title: Therapeutic vaccines against chronic hepatitis-B virus and related complications  
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan
## Keynote Forum

### Opening Ceremony

**Keynote Forum**

**Introduction**

**Allan Cripps**  
Pro Vice Chancellor, Griffith University, Australia

**Nikolai Petrovsky**  
President, Global Vaccines conferences, OMICS International,  
Research Director, Vaxine, Australia

### Coffee Break:

| Track 1: Technologies for The Design, Discovery, Formulation and Administration of Vaccines |
| Track 2: Vaccines For Pregnant Women |
| Track 5: Recent Advances in Animal Vaccination |
| Track 6: Adjuvants for Human / Animal Vaccines |
| Track 9: Advancements in Vaccine Development |

Session Chair: Nikolai Petrovsky, President, Global Vaccines conferences, OMICS International, Research Director, Vaxine, Australia

### Session Introduction

**Title:** Rational vaccine design against complex pathogens in the OMICS era  
Denise Doolan, QIMR Berghofer, Australia

**Title:** Development of a Passive RSV Vaccine for Infants as an Alternative to Maternal Vaccination  
Filip Dubovsky, MedImmune/AstraZeneca, USA

**Title:** A dendritic cell-targeted vaccine loaded with a glyceraldehyde-3-phosphate dehydrogenase peptide confers wide protection to listeriosis in susceptible and resistant mice  
Carmen Alvarez-Dominguez, Proteomics and Vaccines, Spain

**Title:** Development and assessment of multivalent recombinant vaccines for bovine respiration disease  
Timothy J Mahony, The University of Queensland, Australia

**Group Photo**

### Lunch Break & Networking:

**Title:** Advax-adjuvanted killed Japanese Encephalitis Virus (JEV) vaccine is safe in pregnant mares and in foals and induces robust immunological memory  
Helle Bielefeldt-Ohmann, Australian Infectious Diseases Research Centre, Australia

**Title:** Achievements and challenges in post-exposure vaccine development  
Yuzhang Wu, The Third Military Medical University, China

**Title:** Novel non-genetic approach to improve the tuberculosis vaccine BCG  
Zakaria Hmama, University of British Columbia, Canada

### Keynote Talk

**Kenneth Beagley**  
Deputy director, The leader of the Infectious Disease Research Program  
Institute of Health Biomedical Innovation (IHBI)  
Queensland University of Technology, Australia

**Title:** Chikungunya Virus vaccines?  
Andreas Suhrbier, QIMR Berghofer Medical Research Institute, Australia

**Coffee Break:**
Title: Kunjin replicon-based vaccine candidate against Ebola virus
Alexander Khromykh, Australian Infectious Diseases Research Centre, Australia

Title: Future prospect of mosquito salivary components as novel target for vector based vaccine against Dengue: Molecular characterization of immunomodulatory protein from salivary glands of Aedes aegypti
Kartika Senjarini, University of Jember Indonesia, Indonesia

Title: Using carriage surveillance to show direct and indirect effects of pneumococcal conjugate vaccine
Fiona Russell, The University of Melbourne, Australia

Panel Discussion

Day 2    July 28, 2015

Keynote Forum

Mohammed Alsharifi
Director, Chief Scientific Officer, Gamma Vaccines, Australia

Roy Hall
Professor of virology, The University of Queensland, Australia

Track 11: Protein Subunits- Vaccination
Track 12: Toxoid vaccines and its importance
Track 14: Vaccines Under Research and Development, Major Diseases
Track 15: Innovative Development of Vaccines
Track 16: Mucosal vaccines

Session Chairs: Kenneth Beagley, Queensland University of Technology, Australia
Roy Hall, Professor of virology, The University of Queensland, Australia

Session Introduction

Title: Recruitability and Retention: The Challenges of Vaccine Trial design
Suzanne L. Elliott, Q-Pharm, Australia

Coffee Break

Title: Gamma-ray Inactivated Vaccines: Concepts and Applications
Lew-Tabor, The University of Queensland, Australia

Title: Nasal vaccine using nanoparticles against toxoplasma gondii infection: A mechanistic study
Didier Betbeder, University of Lille, France

Title: Unique IL-4R antagonist and IL-13Ra2 adjuvanted pox viral vector-based HIV vaccines
Charaní ranasinghe, Australian National University, Australia

Title: Antigen-displaying polyester particles manufactured by engineered bacteria
Bernd Rehm, Massey University, New Zealand

Lunch Break & Networking

Young Research Forum

Title: Towards the development of oral vaccine delivery systems for lipid core peptide-based vaccines using novel multi-layer engineered nanoliposomes against Group A streptococcus
Nirmal Marasini, The university of Queensland, Australia

Title: A Protective Immune Response Using Asymmetric Multi-Epitope Self-Adjuvanting lipopeptide Vaccine Model
Sharareh Eskandari, The University of Queensland, Australia

Title: Binding and immune modulation properties of mannosylated lipo-peptide vaccines
Bita Sedaghat, The University of Queensland, Australia

Title: Best practice for communicating pertussis booster vaccine recommendations to new mothers: A randomised-control trial
Elizabeth Helen Hayles, Division of Women's and Children's Health, Australia

Title: Liposomes as a Delivery Platform of Vaccines Against Group A Streptococcus
Khairunnisa Abdul Ghaftar, University of Queensland, Australia

Video Session

Title: Capsular polysaccharide loaded chitosan nanoparticles for mucosal immunization via respiratory tract against Klebsiella Pneumonia
Mala Menon, Bombay College of Pharmacy, India

Panel Discussion

Poster Session & Coffee Break

P1
Title: New adjuvant G3/DT induces protective T cell response with a split-virion influenza vaccine
Jan Fohlman, Växjö and Uppsala University, Sweden
Title: Enhanced Immunogenicity of A Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Formulated with Advax Adjuvant
Hiroko Toriniwa, Kitasato daiichi sankyo vaccine co., Ltd. Japan

Title: Lipid core peptide nanoparticles as effective delivery system to trigger humoral immune responses against Group A streptococcus (GAS)
Saranya Chandrudu, University of Queensland, Australia

Title: Optimization of nuclear-localization in a Multicomponent Non-viral Gene Delivery System
Wei Dai, University of Queensland, Australia

Title: Targeting antigenic site on RSV F protein associated with virus neutralization for vaccine design
Noushin Jaberolansar, University of Queensland, Australia

Title: Peptide-based self-assembled nanovaccine system targeting Group A Streptococcus infection
Guangzu Zhao, University of Queensland, Australia

---

**B2B Meetings**

**Day 3**
**July 28, 2015**

---

**Keynote Forum**

**Istvan Toth**
ARC Australian Professorial Fellow, Chair-Biological Chemistry
Professor of Pharmacy, Director of Pharmaceuticals TetraQ
Group Leader, IMB Division of Structural Biology,
The University of Queensland, Australia

---

**Track 2: Developing Next-Gen Conjugate Vaccines**
**Track 17: Childhood vaccines**
**Track 18: Cancer vaccines**
**Track 20: Delivery Technologies**
**Track 21: Vaccines Business and Development**

**Session Chair:** Mohammed Alsharifi, Director, Chief Scientific Officer, Gamma Vaccines, Australia

---

**Session Introduction**

**Title:** Vaccine Manufacturing and Clinical Trial Services for Diarrheal Disease Product Development
Rodolfo M. Alarcón, NIH, USA

**Title:** Anti-cancer telomerase vaccines: Are they entering the age of maturity?
Gilberto Filaci, Professor, University of Genoa, Italy

**Coffee Break**

**Title:** Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and USA
Simon John Potter, Principal, Spruson & Ferguson, Australia

**Title:** Silica nanocarriers for delivery of single dose – shelf stable nano vaccines
Neena Mitter, The University of Queensland, Australia

**Title:** Rotavirus vaccines: Development, implementation and impact
Julie E. Bines, University of Melbourne, Australia

**Title:** How promising is the development of a meningococcal semi-synthetic conjugate vaccine? - a case study
Manoj Kumar Chhikara, Hillman Labs, India

**Title:** Non-targeted effects of childhood vaccines: Epidemiological evidence and emerging immunological mechanisms
Katie Flanagan, Monash University, Australia

**Lunch Break**

**Title:** Key steps in moving a vaccine from proof of concept in mice to human clinical trials
Mark Reid, Clinical Network Services (CNS) Pty Ltd, Australia

**Title:** Use of system biology to identify genes associated with enhanced immunogenicity to a skin patch (nanopatch) delivered vaccine
Germain J. P. Fernando, University of Queensland, Australia

**Title:** Immunisation using microspheres of poly glycidyl methacrylate functionalized with MSA-2 peptide to protect cattle from babesiosis
Manuel Rodriguez-Valle, QAAFI/Centre for Animal Science, Australia

**Title:** A Novel Quantitative Fluorescence Spectroscopy Method to Estimate the Surfactant-Induced Split Ratio of Influenza Virus
Veysel Kayser, The University of Sydney, Australia

---

**Panel Discussion**

**Award Ceremony**